SavedAdd your journal

Journals / Türk Jinekoloji ve Obstetrik Derneği Dergisi / 2011 / Cilt: 8 - Sayı: 1

Liposomal doxorubicin-related palmar-plantar erthrodysesthesia (hand-and foot syndrome): Report of a case

Lipozomal doksorubisin ile ilişkili palmar-plantar eritrodisestezi (el-ayak sendromu): Olgu sunumu ve derleme

Çağdaş ŞAHİN
Bülent KARABULUT
Yılmaz DİKMEN
Aydın ÖZSARAN
Mustafa Coşan TEREK
Pages
62–66
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After the disease is estbalished the treatment consists of lowering the drug dosage, prolonging the dose intervals or discontinuing the drug as well as using topical agents.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Palmar-plantar erthrodyesthesıa (PPE) (hand and foot syndrome) is a dermatological toxic reaction related to some chematherapeutic agents.
📊
Key Findings & Data:Liposomal doxorubicin is the long-acting formula of doxorubisin and it causes PPE in 50% of the patients when used with the dosage of 50 mg/m2.
💡
Conclusion & Impact:After the disease is estbalished the treatment consists of lowering the drug dosage, prolonging the dose intervals or discontinuing the drug as well as using topical agents.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Palmar-plantar erthrodyesthesıa (PPE) (hand and foot syndrome) is a dermatological toxic reaction related to some chematherapeutic agents. Liposomal doxorubicin is the long-acting formula of doxorubisin and it causes PPE in 50% of the patients when used with the dosage of 50 mg/m2. The disease causes burning sensation in the hands and feet and then shows progression by edema and erythema. After the disease is estbalished the treatment consists of lowering the drug dosage, prolonging the dose intervals or discontinuing the drug as well as using topical agents.

Özet

Palmar-plantar eritrodisestezi (PPE) (el-ayak sendromu) bazı kemoteröpötik ilaçlar ile ilişkili dermotolojik toksik reaksiyondur. Lipozomal doksorubisin konvansiyonel doksorubisin’in uzun salınımlı bir formülüdür ve 4 haftada bir 50 mg/m2 kullanıldığında hastaların %50’sinde PPE görülmektedir. Hastalık özellikle el ve ayaklarda yanma hissi ile ortaya çıkmakta daha sonra ilerleyerek ödem ve eritem meydana gelmektedir. Hastalık geliştikten sonra ise tedavi ilaç dozunun azaltılması, doz aralıklarının uzatılması ya da ilacın kesilmesiyle birlikte çeşitli topikal ajanların kullanılması şeklindedir.

🔖

Cite This Article

ŞAHİN, Ç., KARABULUT, B., DİKMEN, Y., ÖZSARAN, A., TEREK, M. C. (2022). Liposomal doxorubicin-related palmar-plantar erthrodysesthesia (hand-and foot syndrome): Report of a case. Türk Jinekoloji ve Obstetrik Derneği Dergisi, Cilt: 8 - Sayı: 1, 62–66. https://ajindex.com/articles/631604

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome: incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225- 34
  2. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 798-9
  3. O’Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440- 9
  4. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma:a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312- 22
  5. Rifkin RM, Gregory SA, Mohrbacher A et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 2006; 106: 848- 58
  6. Jacobi U, Waibler E, Schulze P et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 2005; 16: 1210- 1
  7. Zuehlke KL. Erythematous eruption of palms and roles associated with mitotane therapy. Dermatologica 1974; 148: 90- 2
  8. Bhasin S, Sunita, Gupta DK et al. Chemotherapy-induced palmer planter erythrodysesthesia. J Assoc Physicians India 2005; 53: 155- 6
  9. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89: 1037- 47
  10. Edwards SJ. Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer. Semin Oncol Nurs 2003; 19: 19- 9
  11. Molpus KL, Anderson LB, Craig CL et al. The effect of regional cooling on toxicities associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol 2004; 93: 513- 6
  12. Gyorgy P, Eckardt R. Vitamin B6 and skin lesions in rats. Nature 1939; 144: 512
  13. Fabian CJ, Molina R, Slavik M et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continous 5-fluorouracil infusion. Invest New Drugs 1990; 8: 57- 63
  14. Drake RD, Lin WM, King M et al. Oral dexamethasone attenuates Doxil_-induced palmar-plantar erythrodysesthesi